Completed Cancer NIHR-supported project Digestion, Kidneys & Other Organs
A Phase 3, Open-label, Multicenter, RandomizedStudy of Xaluritamig vs Cabazitaxel or SecondAndrogen Receptor-Directed Therapy inSubjects With Metastatic Castration-ResistantProstate Cancer Previously Treated WithChemotherapy
About this grant
This summary is based on the grant title only — the full abstract was not available.
No substantive source abstract was published for this research project funded by NIHR.
Researchers
Mark Linch (Principal Investigator)
Related Research
Grants with similar aims, by meaning.
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer
A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Naïve Men with Progressive Metastatic Castrate Resistant Prostate Cancer
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer
A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Original classification
CancerPlain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know